Phase 3 trial results released by Protagonist Therapeutics has revealed that icotrokinra, an oral IL-23 receptor inhibitor, achieved clear or nearly clear skin in 66% of patients with ...

Icotrokinra led to high rates of skin clearance in patients with scalp and genital psoriasis, according to results from the ICONIC-TOTAL study.

MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update ...

Johnson & Johnson (J&J) and Protagonist Therapeutics’ investigational oral peptide icotrokinra (JNJ-2113) has been associated ...

The primary endpoint was met, with 57% of subjects treated with the therapy achieving clear or almost clear skin.

J&J announces positive data from phase 3 ICONIC-TOTALa study of icotrokinra to treat scalp and genital psoriasis: Spring House, Pennsylvania Monday, May 12, 2025, 11:00 Hrs [IST] ...

House: Johnson & Johnson has announced new data from the Phase 3 ICONIC-TOTAL study investigating icotrokinra (JNJ-2113), the ...

She loves testing health products, like sports bras and foot spas, and hitting snooze on her alarm. If you’ve ever had a professional pedicure, you know the indulgent delight they bring ...

of patients with scalp psoriasis and 77% with genital psoriasis treated with investigational icotrokinra achieved site-specific clear or almost clear skin ...

1 Gooderham, M.J. et al. Phase 3 results from an innovative trial design of treating plaque psoriasis involving difficult-to-treat, high-impact sites with icotrokinra, a targeted oral peptide that ...

Data from icotrokinra ICONIC-TOTAL show 66% of patients with scalp psoriasis and 77% with genital psoriasis achieved site-specific clear or almost clear skin at Week 16Icotrokinra continues to ...

THE MANAGEMENT of plaque psoriasis has evolved significantly over the past two decades, with biologic treatments becoming increasingly central to care. A recent cross-sectional study, analysing data ...